Severe Hepatocellular Injury With Apoptosis Induced by a Hepatitis C Polymerase Inhibitor

Goals To describe the mechanisms of severe hepatocellular injury with apoptosis in 2 patients receiving hepatitis C virus (HCV)-796. Background HCV-796 is a hepatitis C polymerase inhibitor approved by the US Food and Drug Administration for a phase 2 study of the treatment of hepatitis C in combination with PEG-Interferon and ribavirin. Results The injury occurred after more than 12 weeks of treatment, with a >20-fold increase in serum alanine aminotransferase and aspartate aminotransferase, and a marked increase in total (and direct) bilirubin in the absence of cholestasis. There was no evidence of autoimmune or viral hepatitis. Involvement of the mitochondrial apoptotic pathway was demonstrated by (1) release of cytochrome C into the cytosol; (2) association of cytochrome C with apoptotic protease activating factor-1 in the cytosol; (3) activation of initiator caspase 9; (4) activation of effector caspase 3; (5) increased serum caspase-3 cleaved cytokeratin-18 peptide; (6) nuclear fragmentation; (7) mitochondrial structural abnormalities; (8) expression of light chain 3 B, an indicator of autophagy; (9) probable autophagy of mitochondria by autophagosomes; and (10) probable phagocytosis of apoptotic hepatocytes by activated macrophages. Immunoglobulin G immune complexes were identified in the hepatocytes and localized to the endoplasmic reticulum and Golgi of these patients after the drug-induced liver disease, reflecting a primary or secondary target. Hepatitis C treatment was discontinued at weeks 15 and 19 in patients 1 and 2, respectively. After more than 6 months off the medication, both patients normalized the serum alanine aminotransferase, aspartate aminotransferase, and total bilirubin with undetectable HCV RNA. Conclusions HCV-796 may cause severe hepatocellular injury and apoptosis, with a marked immune reaction in susceptible patients.

[1]  M. Buck,et al.  A Ribosomal S-6 Kinase–Mediated Signal to C/EBP-β Is Critical for the Development of Liver Fibrosis , 2007, PloS one.

[2]  M. Omary,et al.  Keratins let liver live: Mutations predispose to liver disease and crosslinking generates Mallory‐Denk bodies , 2007, Hepatology.

[3]  M. Buck,et al.  C/EBPbeta phosphorylation rescues macrophage dysfunction and apoptosis induced by anthrax lethal toxin. , 2007, American journal of physiology. Cell physiology.

[4]  Mark H. Ellisman,et al.  Correlated three-dimensional light and electron microscopy reveals transformation of mitochondria during apoptosis , 2007, Nature Cell Biology.

[5]  Lisa M Yerian,et al.  In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease , 2006, Hepatology.

[6]  M. Madariaga Drug-related hepatotoxicity. , 2006, The New England journal of medicine.

[7]  D. Green At the gates of death. , 2006, Cancer cell.

[8]  G. Gores,et al.  Apoptosis and necrosis in the liver: A tale of two deaths? , 2006, Hepatology.

[9]  D. Green,et al.  Connected to Death: The (Unexpurgated) Mitochondrial Pathway of Apoptosis , 2005, Science.

[10]  Lin Yan,et al.  Autophagy in chronically ischemic myocardium. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Neil Kaplowitz,et al.  Idiosyncratic drug hepatotoxicity , 2005, Nature Reviews Drug Discovery.

[12]  M. Manns,et al.  Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury , 2004, Hepatology.

[13]  G. Gores,et al.  An apoptosis biomarker goes to the HCV clinic , 2004, Hepatology.

[14]  M. Manns,et al.  Immunological Mechanisms in Liver Injury , 2002 .

[15]  D. Larrey Epidemiology and Individual Susceptibility to Adverse Drug Reactions Affecting the Liver , 2002, Seminars in liver disease.

[16]  T. Hunter,et al.  Nuclear export of phosphorylated C/EBPβ mediates the inhibition of albumin expression by TNF‐α , 2001 .

[17]  T. Hunter,et al.  C/EBPbeta phosphorylation by RSK creates a functional XEXD caspase inhibitory box critical for cell survival. , 2001, Molecular cell.

[18]  Ann Daly,et al.  Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression , 2001, Nature Genetics.

[19]  M. Eichelbaum,et al.  CYP3A genetics in drug metabolism , 2001, Nature Medicine.

[20]  Takeshi Noda,et al.  LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing , 2000, The EMBO journal.

[21]  D. Pessayre,et al.  Withdrawal of life support, altruistic suicide, fratricidal killing and euthanasia by lymphocytes: different forms of drug-induced hepatic apoptosis. , 1999, Journal of hepatology.

[22]  B. Persson,et al.  Immunocytochemical detection and mapping of a cytokeratin 18 neo‐epitope exposed during early apoptosis , 1999, The Journal of pathology.

[23]  H. Tsukamoto,et al.  Stimulation of hepatic lipocyte collagen production by Kupffer cell‐derived transforming growth factor β: Implication for a pathogenetic role in alcoholic liver fibrogenesis , 1990, Hepatology.

[24]  J. Fierer,et al.  D-Galactosamine hepatotoxicity is associated with endotoxin sensitivity and mediated by lymphoreticular cells in mice. , 1985, Gastroenterology.